Drug Profile
SPL 2992
Alternative Names: SPL-2992Latest Information Update: 30 Mar 2008
Price :
$50
*
At a glance
- Originator Starpharma
- Class Antivirals; Dendrimers
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B; Liver cancer
Most Recent Events
- 05 Oct 2001 Preclinical development for Liver cancer in USA (Unknown route)
- 04 Oct 2001 Preclinical development for Hepatitis B in Australia (Unknown route)
- 04 Oct 2001 Preclinical development for Hepatitis B in USA (Unknown route)